Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AstraZeneca Japan to Draw on Overseas Dapagliflozin Data to Trump SGLT-2 Rivals
December 16, 2013
- Pfizer Japan to Reorganize in January with Stand-Alone Vaccines Unit
December 16, 2013
- Medipal to Venture into Contract PMS Business, Making Medi-Skette Its Wholly Owned Subsidiary
December 16, 2013
- AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
- Kyowa Kirin, Hisamitsu Launch Cancer Pain Treatment Abstral Sublingual Tablets
December 13, 2013
- IPSN Proposes Life Sciences Business Platform in Tokyo to Be Included in Mr Abe’s Special Zones
December 12, 2013
- Mochida Buys Back 100,000 Shares
December 12, 2013
- New Osaka Logistics Center to Go Live in January: Taisho
December 12, 2013
- Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
- US FDA Advisory Panel Backs Takeda Ulcerative Colitis Drug
December 11, 2013
- Santen Sets Up Local Subsidiary in Singapore
December 11, 2013
- Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
- Ono to Launch PI Study on Peptide-Cocktail Vaccine for HCC
December 11, 2013
- GSK Launches Asthma Treatment Relvar
December 11, 2013
- Drug Makers Invest in Developing AD Treatments
December 10, 2013
- Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
- Santen Files MAA for Ciclosporin for Dry Eye Disease in Europe
December 10, 2013
- Veep Kawasaki to Be Elevated to President of inVentiv Health Japan
December 9, 2013
- Survey Finds 1.7-Fold Increase in Patients Prescribed DPP-4 Inhibitors Over 2-Year Period: MDV
December 9, 2013
- ViiV Healthcare Files NDA for Anti-HIV Treatment Dolutegravir in Japan
December 9, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…